Hosted on MSN
Vericel outlines 23% MACI revenue growth for H2 2025 while advancing OUS expansion and MACI Ankle clinical study
CEO Dominick C. Colangelo highlighted "outstanding financial and business results in the third quarter with strong top line revenue growth and even higher profit growth, a significant inflection in ...
Vericel is rated a hold due to inconsistent growth, fluctuating profitability, and limited near-term upside at current valuation. VCEL's future hinges on scaling MACI, as Epicel and Nexobrid have ...
Vericel Corporation reported record first quarter MACI revenue of $46.3 million, with total revenue of $52.6 million. Vericel Corporation reported record first-quarter 2025 revenues of $52.6 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results